Why did ADMA Biologics (ADMA) stock move recently?

On 7/28/2026, ADMA Biologics moved +3.7% — ADMA rose with the broader market amid no company-specific news or filings; recent coverage focused on ongoing securities class-action lawsuit reminders with an August 10 deadline. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is ADMA Biologics (ADMA) overvalued or fairly valued?

MarketChacha shows ADMA Biologics's valuation in context — a trailing P/E of about 14.6, a forward P/E of about 9.5, a price-to-book of about 5.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is ADMA Biologics's revenue?

ADMA Biologics reported revenue of $510.2M for FY2025, with net profit of $146.9M, per official filings.

What is the share price of ADMA Biologics (ADMA)?

ADMA Biologics last traded at $9.34 (-0.6% on the day), as of 9/1/2026 — a delayed quote shown for education, not investment advice.

ADMA Biologics

ADMA · NYSE · Healthcare · United States

Snapshot

TickerADMA

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees640

HeadquartersRamsey, United States

Websitewww.admabiologics.com

Filings tracked15

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Who owns it

Insiders2.0%
Institutions93.3%
Public & other4.8%

445 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.17.12%
State Street Corporation7.64%
Vanguard Capital Management LLC4.51%
Vanguard Portfolio Management LLC4.50%
Rubric Capital Management LP4.17%
Capital Research Global Investors3.91%
First Trust Advisors LP3.48%
Geode Capital Management, LLC2.71%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years only 0.56× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion0.56×

Net margin trend-10.9% → 28.8%

Margin has expanded by about 39.7 points — the business is getting more profitable.

Return on equity30.8%

Latest ROE of 30.8% — capital is generating a healthy return.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $158.4M · EPS 0.24

Est. earnings growth +12.8%

Next fiscal year

Rev $700.3M · EPS 0.98

Est. earnings growth +23.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$510.2M

Net margin

28.8%

ROE

30.8%

Revenue CAGR (2y)

+40.6%

EPS (FY2025)

0.60

Net profit (FY2025)

$146.9M

Ask MarketChacha about ADMA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 28, 2026
ADMA rose with the broader market amid no company-specific news or filings; recent coverage focused on ongoing securities class-action lawsuit reminders with an August 10 deadline.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$510.2M	$146.9M	0.60	28.8%	30.8%
FY2024	$426.5M	$197.7M	0.81	46.4%	56.6%
FY2023	$258.2M	$-28.2M	-0.13	-10.9%	-20.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$124.4M	$37.8M	0.16	30.4%
2026Q1	$114.5M	$45.3M	0.19	39.6%
2025Q3	$134.2M	$36.4M	0.15	27.1%
2025Q2	$122.0M	$34.2M	0.14	28.1%
2025Q1	$114.8M	$26.9M	0.11	23.4%
2024Q3	$119.8M	$35.9M	0.15	30.0%
2024Q2	$107.2M	$32.1M	0.13	29.9%
2024Q1	$81.9M	$17.8M	0.08	21.7%
2023Q3	$67.3M	$2.6M	0.01	3.8%
2023Q2	$60.1M	$-6.4M	-0.03	-10.6%
2023Q1	$56.9M	$-6.8M	-0.03	-11.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Shareholder vote results
SEC6/2/2026material
8-K — Results of operations, Exhibits
SEC5/6/2026material
10-Q filing
SEC5/6/2026
8-K — Other events, Exhibits
SEC5/4/2026material
8-K — Reg FD disclosure, Exhibits
SEC3/27/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC3/2/2026material
8-K — Results of operations, Executive/director change, Exhibits
SEC2/25/2026material
10-K filing
SEC2/25/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Material agreement, Termination of agreement, Results of operations, Material financial obligation, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.